Concord Wealth Partners - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
Concord Wealth Partners ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2022$2,0000.0%1,5000.0%0.00%0.0%
Q1 2022$2,000
-50.0%
1,5000.0%0.00%0.0%
Q4 2021$4,0000.0%1,5000.0%0.00%
-50.0%
Q3 2021$4,0000.0%1,5000.0%0.00%
+100.0%
Q2 2021$4,0000.0%1,5000.0%0.00%0.0%
Q1 2021$4,0001,5000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$83,313,0005.12%
Defender Capital, LLC. 4,997,870$12,245,0003.92%
Raffles Associates 543,590$1,332,0001.28%
Prescott General Partners LLC 1,851,851$4,537,0000.16%
DCF Advisers, LLC 85,000$208,0000.08%
Long Focus Capital Management, LLC 215,000$527,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$110,0000.06%
DAFNA Capital Management LLC 80,000$196,0000.05%
Strategic Wealth Investment Group, LLC 65,069$159,0000.04%
Fort Sheridan Advisors LLC 52,931$130,0000.04%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders